|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10381039104010411042104310441045104610471048...10631064» |
- |||||||||| New P3 trial, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - May 1, 2013
P3, N=670, Recruiting, Sponsor: Janssen Research & Development, LLC
- | Istodax (romidepsin) / Astellas, BMS
New P1 trial, Combination therapy: Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 1, 2013
P1, N=24, Recruiting, Sponsor: NCIC Clinical Trials Group
- RG4733 / Roche
Trial termination: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (clinicaltrials.gov) - Apr 30, 2013
P1/2, N=129, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated
- pegylated liposomal doxorubicin / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Apr 29, 2013
P2, N=57, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- ||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change: Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray (clinicaltrials.gov) - Apr 28, 2013
P3, N=327, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed N=271 --> 327
- || Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
New P3 trial, P3 data: Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema (clinicaltrials.gov) - Apr 28, 2013
P3, N=52, Recruiting, Sponsor: Technische Universität München
- dasatinib / Generic mfg.
Enrollment closed: First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL (clinicaltrials.gov) - Apr 28, 2013
P2, N=51, Active, not recruiting, Sponsor: The Catholic University of Korea
N=271 --> 327 Recruiting --> Active, not recruiting
- | Enrollment change: Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 27, 2013
P3, N=2500, Recruiting, Sponsor: Prince of Wales Hospital, Shatin, Hong Kong
Recruiting --> Active, not recruiting N=440 --> 2500
- |||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., carfilzomib / Generic mfg.
P3 data: ENDEAVOR: Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (clinicaltrials.gov) - Apr 27, 2013
P3, N=888, Recruiting, Sponsor: Onyx Pharmaceuticals
N=440 --> 2500 Ongoing --> Recruiting
- pomalidomide / Generic mfg.
Clinical: Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma (clinicaltrials.gov) - Apr 25, 2013
P1, N=34, Recruiting, Sponsor: Mayo Clinic
Ongoing --> Recruiting Initiation date: Jan 2013 --> Apr 2013
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment open: Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Apr 25, 2013
P2, N=24, Recruiting, Sponsor: University College, London
Initiation date: Jan 2013 --> Apr 2013 Not yet recruiting --> Recruiting
- ||||| pegvorhyaluronidase alfa (PEGPH20) / Halozyme
New P2 trial, Metastases: HALO-109-202: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer (clinicaltrials.gov) - Apr 23, 2013
P2, N=132, Active, not recruiting, Sponsor: Halozyme Therapeutics
- dexamethasone / Generic mfg.
Trial completion: Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment (clinicaltrials.gov) - Apr 22, 2013
P=N/A, N=36, Completed, Sponsor: Medical University of Vienna
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Trial completion: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Apr 22, 2013
P3, N=498, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
New P4 trial: A Trial of Neuroprotection With ACTH in Acute Optic Neuritis (clinicaltrials.gov) - Apr 21, 2013
P4, N=60, Recruiting, Sponsor: Elliot Frohman
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
P2 data: Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years old : a phase II study of the Intergroupe Francophone du Myélome (IFM) Traitement de première ligne par Carfilzomib, Lenalidomide et Dexamethasone (CRd) en induction suivi par une autogreffe de cellules souches, un traitement de consolidation par CRd et un entretien par Lenalidomide chez les patients de ≤65 ans atteints de Myélome Multiple de novo : une étude de phase II de l’Intergroupe Francophone du Myélome (IFM) (EUDRACT) - Apr 21, 2013
P2, N=46, Ongoing, Sponsor: CHU de Toulouse
- | Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P1 trial: A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma (clinicaltrials.gov) - Apr 21, 2013
P1, N=32, Recruiting, Sponsor: GlaxoSmithKline
- || Oxis Turbuhaler (formoterol) / AstraZeneca, Ventolin (albuterol) / GSK, Oxeze Turbuhaler (formoterol dry-powder inhaler) / AstraZeneca
New P3 trial, HEOR: A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients (clinicaltrials.gov) - Apr 17, 2013
P3, N=360, Not yet recruiting, Sponsor: Henan University of Traditional Chinese Medicine
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion, Combination therapy: Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry (clinicaltrials.gov) - Apr 17, 2013
P3, N=313, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion: Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=121, Completed, Sponsor: Allergan
Recruiting --> Completed Active, not recruiting --> Completed
- Ultibro (glycopyrronium/indacaterol) / Novartis
New P3 trial: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - Apr 16, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- dexamethasone / Generic mfg.
Trial termination: Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone (clinicaltrials.gov) - Apr 16, 2013
P3, N=2, Terminated, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Recruitment problems (not enough patients were found who met eligibility criteria)
- fosaprepitant / Generic mfg.
Trial termination, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
Active, not recruiting --> Terminated; Recruitment problems (not enough patients were found who met eligibility criteria) Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients
- dexamethasone / Generic mfg.
Enrollment change: Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone (clinicaltrials.gov) - Apr 16, 2013
P3, N=2, Terminated, Sponsor: University Hospital Inselspital, Berne
Completed --> Terminated; Study stopped due to lack of efficacy in first 6 patients N=72 --> 2
- fosaprepitant / Generic mfg.
Enrollment change, Metastases: Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (clinicaltrials.gov) - Apr 16, 2013
P2, N=6, Terminated, Sponsor: University of Washington
N=72 --> 2 N=45 --> 6
- | dexamethasone / Generic mfg., epinephrine / Generic mfg.
New P4 trial: Epinephrine, Dexamethasone, and Hypertonic Saline in Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety (clinicaltrials.gov) - Apr 16, 2013
P4, N=120, Recruiting, Sponsor: Hospital General Naval de Alta Especialidad
- ||||| oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2013
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- triamcinolone acetonide / Generic mfg.
Enrollment open: Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management (clinicaltrials.gov) - Apr 10, 2013
P2, N=36, Recruiting, Sponsor: University of Florida
N=45 --> 6 Not yet recruiting --> Recruiting
- fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment change: A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol (clinicaltrials.gov) - Apr 10, 2013
P1, N=36, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=108 --> 36
- | fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol (clinicaltrials.gov) - Apr 10, 2013
P1, N=36, Completed, Sponsor: GlaxoSmithKline
N=108 --> 36 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
- | cisplatin / Generic mfg., pemetrexed / Generic mfg.
Enrollment closed: A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 9, 2013
P2, N=33, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ketoconazole / Generic mfg., dexamethasone / Generic mfg.
Enrollment closed: Ketoconazole and Dexamethasone in Prostate Cancer (clinicaltrials.gov) - Apr 9, 2013
P2, N=32, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| carfilzomib / Generic mfg.
P1/2 data: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1/2, N=235, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Viibryd (vilazodone) / AbbVie
New P2 trial: Vilazodone for Corticosteroid-Induced Memory Impairment (clinicaltrials.gov) - Apr 8, 2013
P2, N=18, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: ORION: Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (clinicaltrials.gov) - Apr 8, 2013
P4, N=45, Recruiting, Sponsor: Valley Retina Institute
- | prednisolone / Generic mfg.
Trial completion: Prednisolone in Infantile Spasms- High Dose Versus Usual Dose (clinicaltrials.gov) - Apr 6, 2013
P3, N=63, Completed, Sponsor: Lady Hardinge Medical College
Recruiting --> Active, not recruiting Recruiting --> Completed
- P2 data: Phase II Study of Simvastatin for Relapsed/Refractory Myeloma (clinicaltrials.gov) - Apr 4, 2013
P2, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
Recruiting --> Completed Recruiting --> Withdrawn
- triamcinolone acetonide / Generic mfg.
Trial initiation date: Early Treatment for Acute ACL Tear (clinicaltrials.gov) - Apr 4, 2013
P2, N=68, Recruiting, Sponsor: Christian Lattermann
Recruiting --> Withdrawn Initiation date: Nov 2012 --> Mar 2013
- P2 data: Phase II Study of Simvastatin for Relapsed/Refractory Myeloma (clinicaltrials.gov) - Apr 4, 2013
P2, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
Initiation date: Nov 2012 --> Mar 2013 N=55 --> 0
- triamcinolone acetonide / Generic mfg.
Enrollment open: Early Treatment for Acute ACL Tear (clinicaltrials.gov) - Apr 4, 2013
P2, N=68, Recruiting, Sponsor: Christian Lattermann
N=55 --> 0 Not yet recruiting --> Recruiting
- everolimus / Generic mfg., docetaxel / Generic mfg.
New P2 trial, P2 data, Metastases: Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open: STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 2, 2013
P2, N=88, Recruiting, Sponsor: Mathias Witzens-Harig
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
New P3 trial: A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 31, 2013
P3, N=717, Completed, Sponsor: GlaxoSmithKline
- midazolam hydrochloride / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Single Dose of Etomidate and Adrenal Cortex (clinicaltrials.gov) - Mar 31, 2013
P4, N=90, Completed, Sponsor: Istanbul University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Trial termination: Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2013
P2, N=85, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Terminated; slow accrual
- PF-06291874 / Pfizer
Trial completion: Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Mar 31, 2013
P1, N=8, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated; slow accrual Recruiting --> Completed
- || prednisone delayed-release tablet / Generic mfg.
New P3 trial: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 27, 2013
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
- |||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 27, 2013
P2, N=60, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Completed
- triamcinolone acetonide topical / Generic mfg.
Enrollment closed: NdYag Laser for Acne Keloidalis Nuchae (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Henry Ford Health System
Not yet recruiting --> Completed Completed --> Active, not recruiting